SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Techniclone (TCLN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Maurice Winn who wrote (2428)8/15/1998 2:41:00 PM
From: Pseudo Biologist  Read Replies (1) of 3702
 
Maurice, here is a link to a short note in the most recent issue the New England Journal that ought to be of interest to TCLNers:

The New England Journal of Medicine -- August 13, 1998 -- Volume 339, Number 7
Vascular Targeting as a Strategy for Cancer Therapy

nejm.org

Also, I did *quick* medline search for preclinical data on TNT. This is what I could find, from "Cancer Research" back in 1989:

ncbi.nlm.nih.gov

I understand that the TNT antigen (some histone?) is fairly conserved across species and that *the* TCLN TNT antibody recognizes the target in a variety of species, including mice. Given this, I would think that by now we would have a lot more preclinical information about this molecule. The TCLN web page has a few pictures of the action of this molecule, but I may have missed the reference to a publication. Or maybe I have not looked hard enough.

PB
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News